Prodapt Joins the MuleSoft Technology Partner Program
14.9.2022 14:50:00 EEST | Business Wire | Press release
Prodapt today announced it has joined the MuleSoft Technology Partner Program and has contributed to the partner ecosystem by releasing a “MuleSoft Certified Connector for Aria”. The "Aria connector" accessible in Anypoint Exchange will allow companies to simplify integration to Aria and expose convenient methods for taking full advantage of the capabilities of Aria’s Billing and Monetization Platform.
Prodapt is helping its customers integrate Salesforce and Aria faster by using this Anypoint connector. It helps configure and expedite:
- Synch Account Info, Product Info, Billing & Invoice related Info b/w Salesforce and Aria
- Simplified authentication and easily adaptable to new changes
- Speed up the integration by 5x, enable customers to view their billing, invoice, and charges in real-time and improve customer satisfaction.
“As enterprises globally see exceptional value in building IT ecosystems using best-of-breed cloud applications, minimizing and simplifying integration costs using tried and tested best practices are critical for time-to-market and assurance. Prodapt’s MuleSoft Certified Connector for Aria adds to this maturing and growing ecosystem, to significantly simplify integration,” said Brendan O’Brien, Chief Innovation Officer, and Co-Founder, Aria Systems.
“Industries are facing new demands that push them to accelerate the pace of digital transformation,” said Brian Miller, senior vice president of business development, MuleSoft. “The Connectivity Benchmark Report shows that integration challenges are slowing down critical digital initiatives for 88% of organizations. This collaboration allows our mutual customers to create a composable enterprise by securely unlocking and integrating their data and apps to deliver new levels of speed, agility, and efficiency.”
The MuleSoft Technology Partner Program includes leading enterprise software companies across functional applications, such as CRM, enterprise resource planning (ERP), marketing automation, and HCM, as well as across industries, including financial services, healthcare, retail and media, and telecom. Using MuleSoft, technology partners help customers achieve greater speed, agility, and efficiency. MuleSoft’s platform enables companies to become composable businesses, where they can turn every asset in their organization — data, bots, and applications — into reusable building blocks to scale and increase the speed of work.
MuleSoft customers can learn more about Prodapt’s MuleSoft Certified Connector for Aria by visiting: https://www.mulesoft.com/exchange/com.mulesoft.connectors/mule-aria-crescendo-connector/
Prodapt customers can learn more about how to integrate data from siloed apps and systems faster and automate complete workflows more efficiently with MuleSoft at: https://www.mulesoft.com/platform/enterprise-integration.
About Prodapt
Prodapt has a singular focus on the Connectedness vertical. Prodapt partners with the leading creators of our hyper-connected world. Prodapt’s customers range from telecom operators, digital/multi-service providers (D/MSPs), technology and digital platform companies in the business of Connectedness.
Prodapt builds, integrates, and operates solutions enabling next-generation technologies and innovations. Prodapt services global leaders including Google, Facebook, Amazon, Microsoft, AT&T, Verizon, CenturyLink, Adtran, Vodafone, Liberty Global, Windstream, Virgin Media, Rogers, Deutsche Telekom, among many others. Prodapt’s customers help more than a billion people, and five billion devices stay connected.
Prodapt has offices in North America, Europe, Latam, India, and Africa. It is part of the 120-year-old business conglomerate, The Jhaver Group, which employs over 22,000 people across 64+ locations globally.
Salesforce and others are among the trademarks of salesforce.com, inc.
MuleSoft is a registered trademark of MuleSoft, Inc., a Salesforce company. All other marks are those of respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005494/en/
Contact information
Manian Sivaramakrishnan,
Head - Enterprise Marketing
maniannagasubra.s@prodapt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
